Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Seminar luncheon

Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics


Speakers: John Sninsky, PhD, CSO-CIO of Molecular Stethoscope
Organizers:
Date: 2024-06-20
Time: 11:00-14:30 Pacific Time
Registration fee: Vendor Show: $695; Regular attendees:: Free
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date: (2)Agilent Technologies; HICOMP MicroTech Co. Ltd
Registration: http://www.PBSS.org
Registration deadline:2024-06-19  (it will close sooner if the seating cap is reached)

About the Topic

Vendor Show registration is open

Regular attendees' registration will open on May 20th, 2024


About the Speakers

John J Sninsky, PhD, is CSO-CIO for Superfluid Dx, an early-stage biotechnology company with a disease agnostic pioneering cell free mRNA platform that uses NGS and machine learning to develop classifiers for compelling unmet clinical needs. Superfluid Dx has prioritized Alzheimer’s Disease. John has a comprehensive and deep understanding of the development and application of pioneering molecular procedures and bioinformatics to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests as well as diagnostic tests paired with pharmacotherapies.  John is the author of more than 115 scientific papers including advanced methods in molecular biology and next generation sequencing. He spent 30 years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and small to enterprise in vitro diagnostic companies that required FDA clearance and approval for commercialization of kits. He lectures at and advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST). John is a Visiting Professor in the Division Infectious Diseases and Vaccinology in School of Public Health at UC Berkeley. He mentors Biomedical Data Science projects for the Data Mine at Purdue University.


2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/26/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad